Reprogramming the specificity of sortase enzymes Edited by David Baker, University of Washington, Seattle, WA, and approved August 12, 2014 (received for review June 15, 2014) Staphylococcus aureus sortase A catalyzes the transpeptidation of an LPXTG peptide acceptor and a glycine-linked peptide donor and has proven to be a powerful tool for site-specific protein modification. The substrate specificity of sortase A is stringent, limiting its broader utility. Here we report the laboratory evolution of two orthogonal sortase A variants that recognize each of two altered substrates, LAXTG and LPXSG, with high activity and specificity. Following nine rounds of yeast display screening integrated with negative selection, the evolved sortases exhibit specificity changes of up to 51,000-fold, relative to the starting sortase without substantial loss of catalytic activity, and with up to 24-fold specificity for their target substrates, relative to their next most active peptide substrate. The specificities of these altered sortases are sufficiently orthogonal to enable the simultaneous conjugation of multiple peptide substrates to their respective targets in a single solution. We demonstrated the utility of these evolved sortases by using them to effect the site-specific modification of endogenous fetuin A in human plasma, the synthesis of tandem fluorophoreprotein-PEG conjugates for two therapeutically relevant fibroblast growth factor proteins (FGF1 and FGF2), and the orthogonal conjugation of fluorescent peptides onto surfaces.
protein evolution | enzyme specificity T he laboratory modification of proteins enables applications including the manipulation of protein pharmacokinetics (1), the study of protein biochemistry (2) , the immobilization of proteins (3) , and the synthesis of protein-protein fusions that cannot be expressed in cells (4) . An attractive approach for the synthesis of protein conjugates attaches molecules site specifically to proteins using epitope-specific enzymes. Such a strategy can overcome the challenges of bioorthogonality and chemoselectivity through the careful choice of enzyme and epitope. Techniques to implement this approach, however, are commonly limited by the requirement of cumbersome and poorly tolerated fusion epitopes, or by rigidly defined enzyme substrate specificity.
The bacterial transpeptidase Staphylococcus aureus sortase A (SrtA) mediates the anchoring of proteins to the bacterial cell wall and has been widely used in bioconjugate synthesis (5) . Wild-type SrtA binds a small, five-amino acid "sorting motif" (Leu-Pro-XThr-Gly, LPXTG, where X = any amino acid) and cleaves the scissile Thr-Gly peptide bond via a cysteine protease-like mechanism, resulting in loss of the C-terminal glycine to yield a thioacyl intermediate. This intermediate reacts with an N-terminal Gly-GlyGly motif to generate a -LPXTGGG-product (Fig. 1A) . The small size of the sorting motif and the synthetic accessibility of Gly-GlyGly-linked substrates have led to the use of SrtA in a many applications including the synthesis of protein-protein (4), protein-nucleic acid (6), protein-lipid (7), and protein-surface (8) conjugates.
The utility of wild-type SrtA has been limited by two main factors. First, its poor catalytic activity reduces reaction yields and can lead to stable thioacyl intermediates, limiting the use of wild-type SrtA to small-scale bioconjugate synthesis in which superstoichiometric enzyme loadings and long time scales are tolerated. To overcome this limitation, we recently developed a system for the evolution of bond-forming enzymes based on yeast display (Fig. 1B) , and applied the system to evolve a highly active SrtA variant, evolved sortase A (eSrtA), with five mutations relative to wild-type SrtA and ∼140-fold higher catalytic activity (9) .
A second limitation of both SrtA (10) and eSrtA is their requirement for substrates containing LPXTG (see Fig. 3 ). This constraint precludes the use of these enzymes to modify endogenous proteins lacking this particular sequence and also prevents their use in more complex syntheses in which multiple sortase enzymes conjugate orthogonal substrates onto a single protein scaffold or onto multiple protein targets simultaneously. Previous approaches to address this limitation have included the directed evolution of a promiscuous but catalytically impaired SrtA variant recognizing XPETG motifs (11) , as well as the use of a homologous natural sortase enzyme capable of accepting the orthogonal substrate LPETA (12) . These approaches, however, have thus far been unable to generate sortase enzymes with even the modest activity of wild-type SrtA or the specificity levels of natural sortases (11) (12) (13) .
In this work we developed and applied a modified bondforming enzyme screening system to enable the laboratory evolution of SrtA variants with dramatically altered, rather than broadened, substrate specificity. Over nine rounds of mutagenesis and screening with concomitant refinement of our library design and screening strategy, we evolved "reprogrammed" eSrtA variants that recognize either LPXSG or LAXTG with up to a 51,000-fold change in specificity and minimal loss of activity relative to eSrtA. We used one of the altered sortases to achieve the posttranslational modification of endogenous fetuin A in human plasma, which cannot be efficiently modified by eSrtA because it lacks an LPXTG motif. In addition, we used the reprogrammed sortases to mediate the rapid synthesis of doubly modified fluorophore-protein-PEG conjugates. Finally, we used the evolved sortases to immobilize orthogonal fluorophorelinked peptides onto GGG-conjugated surfaces. Collectively, these findings establish a facile approach for generating sortase
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The modification of proteins has proven to be crucial for many research and industrial applications. The bacterial transpeptidase Staphylococcus aureus sortase A (SrtA) is a powerful tool for conjugating proteins to a wide variety of molecules, but is limited to those proteins containing the five amino acid LPXTG sorting motif. Here we present a system for the directed evolution of reprogrammed SrtA variants that accept proteins with altered sorting motifs. We used this system to evolve two families of orthogonal sortases that recognize LAXTG and LPXSG motifs. These evolved sortases enabled the synthesis of triblock fluorophore-protein-PEG conjugates, the covalent and orthogonal functionalization of multiple proteins onto surfaces, and the manipulation of endogenous human proteins lacking a native LPXTG motif.
enzymes with tailor-made substrate specificities and greatly expand the number of highly active, orthogonal sortase enzymes available for protein conjugation applications.
Results
A Competitive Inhibition Strategy for Sortase Evolution. To enable the evolution of eSrtA variants with altered substrate specificity, we modified our previously described yeast display screen (9) with the addition of a negative selection against recognition of off-target substrates (Fig. 1B) . We hypothesized that presenting an enzyme with a limiting quantity of biotinylated target substrate in the presence of a large excess of nonbiotinylated offtarget substrate, followed by a fluorescence-activated cell sorting (FACS)-based screening for biotinylated cells, would favor enzymes with both high activity and high specificity. We envisioned that positive and negative selection pressures could be modulated by varying the concentrations of biotinylated target substrate and nonbiotinylated off-target substrates.
To test the ability of cognate LPETG substrate (K m = 0.2 mM) to compete with a candidate LAETG target (K m = 6.1 mM) in our system, we used Saccharomyces cerevisiae displaying eSrtA and GGG on the cell surface as previously described (9) . We incubated these cells with 10 μM biotin-LAETG and a range of 100 nM to 1 mM nonbiotinylated LPETG for 1 h (SI Appendix, Fig. S1 ). We observed 50% inhibition of cell biotinylation with 10 μM LPETG, and virtually complete inhibition by 100 μM LPETG. These results suggest that in the context of our screen, the K i of a free competitive substrate is substantially more potent than its K m when treated as a substrate, possibly because the single-turnover nature of the yeast display system strongly penalizes candidate enzymes that accept nonbiotinylated substrates.
Initial Evolution of eSrtA Variants with Altered Substrate Preference.
Because binding-pocket geometries of SrtA in previously reported structures are diverse (14-16), we used broad, unbiased mutagenesis to generate initial eSrtA diversity. We randomized the SrtA gene (441 bp) at a 2% mutation level using chemical mutagenesis, transformed the resulting gene pool into yeast to generate libraries of 10 7 to 10 8 eSrtA variants, and screened the resulting libraries after incubation with either biotin-LAETG or biotin-LPESG in the presence of various concentrations of LPETG as a competitive inhibitor (SI Appendix, Table S4 ). Starting eSrtA exhibits a 103-fold preference for LPETG over LAETG, and a 5-fold preference for LPETG over LPESG ( Fig. 2A) .
Three rounds of whole-gene mutagenesis and screening yielded two converged clones, eSrtA(2A-3) and eSrtA(4S-3), each of which contained between 8 and 10 coding mutations relative to eSrtA (Fig. 2B) . Using an established HPLC assay (17), we determined that mutants eSrtA(2A-3) and eSrtA(4S-3) exhibited substantially altered substrate preferences of 1.4-fold preference for LPETG over LAETG (reduced from 103-fold) and a 245-fold preference for LPESG over LPETG (reversed from a 5-fold preference for LPETG), but at the expense of >10-fold reduced catalytic efficiency ( Fig. 2A) . By analyzing the mutations that emerged after round 3 in the context of the SrtA(LPET) NMR structure, we identified a cluster of three mutations in each mutant that are predicted to make contacts with the LPETG substrate in eSrtA. In the case of eSrtA(2A-3), these mutations are K162R, V168I, and I182F, whereas in the case of eSrtA(4S-3), these changes are A104T, A118T, and I182V ( Fig. 2 B-D) . We hypothesized that V168I and I182F collectively may provide additional steric bulk to complement the smaller alanine side chain at substrate position 2, and A104T and A118T may alter active site geometry to discriminate the extra methyl group in threonine versus serine at substrate position 4.
To test this hypothesis, we generated minimal mutants eSrtA (2A-3.5) and eSrtA(4S-3.5) containing only those three mutations corresponding to predicted first-shell contacts in each enzyme (Fig. 2B ). Both minimal mutants exhibited substrate promiscuity, processing LPETG and their new LAETG or LPESG targets with comparable efficiency ( Fig. 2A) , albeit with ∼100-fold lower activity than that of eSrtA on its native LPETG substrate. Whereas these variants showed dramatically reduced performance in nearly 
Characteristics of evolved sortase enzymes. The most abundant clone from each round was expressed and purified from E. coli, then (A) characterized using an HPLC assay (SI Appendix, Table S3 ). The predominant round 9 clone targeting LAETG exhibited a 51,000-fold change in specificity for LAETG versus LPETG relative to eSrtA. Similarly, the predominant round 9 clones targeting LPESG exhibited 125-fold changes in specificity for LPESG versus LPETG. all respects relative to round 3, their broad substrate scope suggested they might serve as fertile starting points for the further evolution of altered sortase specificity.
Secondary Evolution of eSrtA Variants with Altered Substrate Specificity.
Next we generated site-saturation libraries based on the eSrtA(2A-3.5) and eSrtA(4S-3.5) minimal mutants. Using degenerate NNK codons, we randomized residues 104, 168, and 182 in eSrtA(2A-3.5), and residues 104, 118, and 182 in eSrtA(4S-3.5). Additionally, we used PCR mutagenesis to further diversify these libraries in an untargeted manner at a mutation rate of ∼1% per residue. Screening of these libraries against their target substrates in the presence of 10-fold higher concentrations of nonbiotinylated LPETG yielded the round 4 consensus variants eSrtA(2A-4) and eSrtA(4S-4), each of which acquired novel mutations (Fig. 2B ) and between 2-fold (LPESG) and 73-fold (LAETG) preference for their target substrates over LPETG.
Repeating this process, we applied NNK mutagenesis to the most frequently mutated residues among clones emerging from round 4 [positions 162, 168, and 182 in eSrtA(2A-4), and positions 118, 122, and 182 in eSrtA(4S-4)] and also mutated the rest of the eSrtA gene at a ∼1% frequency. Screening of the resulting libraries yielded consensus variants eSrtA(2A-5) and eSrtA(4S-5), each of which included a mixture of mutations at targeted and untargeted residues (Fig. 2B) . Expression, purification, and assaying of these round 5 clones revealed that each of these variants showed considerably improved activity and specificity relative to their round 4 counterparts ( Fig. 2A) .
Finally, we repeated this approach of saturation mutagenesis on each of the newly discovered mutations, as well as the original five mutations in eSrtA. Starting from eSrtA(2A-5), we combined five libraries in which positions 99 and 138 were randomized, in addition to residue 160, 165, 189, 190, or 196 . Similarly, starting from eSrtA(4S-5), we randomized position 132, in addition to residue 160, 165, 189, 190, or 196, before combining the resulting five libraries. Screening provided consensus variants eSrtA(2A-6) and eSrtA(4S-6). These variants exhibited only marginal improvements in catalytic activity and specificity relative to round 5 clones ( Fig. 2A) , suggesting that additional targeted mutagenesis would not yield further gains in performance.
Given that substrate specificity and catalytic activity were comparable among clones emerging from rounds 5 and 6, we hypothesized that the advantage of eSrtA(2A-6) and eSrtA(4S-6) over their ancestors could arise from reduced substrate hydrolysis. To decouple hydrolysis from overall enzymatic efficiency, we measured the concentration of GGG at which the rates of acyl-enzyme hydrolysis and transpeptidation are equal, which we define as the parameter K H . We found that eSrtA(2A-6) (K H = 149 ± 63 μM) possessed significantly improved hydrolytic stability compared with eSrtA(2A-5) (K H = 731 ± 235) and that eSrtA(4S-6) (K H = 116 ± 10 μM) was also improved relative to eSrtA(4S-5) (K H = 190 ± 16 μM).
Taken together, these results suggest that the use of whole-gene mutagenesis to identify target loci for targeted mutagenesis provides access to eSrtA variants with altered substrate specificities. Despite the strong gains observed in rounds 4 and 5, however, we observed no significant activity gains in round 6, suggesting that these evolved enzymes were in a local fitness maximum.
Evolving Highly Active eSrtA Mutants with Altered Specificities. In an effort to escape putative fitness maxima, we partially randomized all of the residues mutated among clones in rounds 4, 5, and 6. For each target site, we created degenerate codon libraries with a 27% mutagenesis rate at each nucleotide of each codon observed to change from our eSrtA starting scaffold. We applied this scheme to residues 94, 98, 99, 104, 160, 162, 165, 182, 189, 190, and 196 in both eSrtA(2A-6) and eSrtA(4S-6) and further applied broad spectrum mutagenesis to each library at a level of ∼1%.
Beginning from this highly mutated starting material, we screened each successive library with gradually increasing stringency by decreasing incubation times before sorting to only 5 min in round 7 (SI Appendix, Table S4 ). The round 7 survivors were randomly mutagenized and rescreened at 5-min incubation times, decreased concentrations of biotinylated substrate, and/or increased concentrations of nonbiotinylated LPETG, yielding libraries 8 and 9 (SI Appendix, Table S4 ). These libraries converged on clones eSrtA(2A-9) and eSrtA(4S-9), each possessing four or five mutations relative to their round 6 counterparts. These mutants were highly active on their target substrates and minimally active on LPETG. The overall changes in substrate specificity of eSrtA(2A-9) and eSrtA(4S-9) relative to eSrtA are 51,000-and 120-fold, respectively ( Fig. 2A) . Differential scanning fluorimetry revealed that both eSrtA(2A-9) and eSrtA(4S-9) possess increased stability (ΔT m = ∼4.4°C) compared with eSrtA (SI Appendix, Fig. S9A ).
Clone eSrtA(4S-9) exhibited strong preference for LPESG over LPETG (25-fold) that was greater than eSrtA's opposite starting preference for LPETG over LPESG (5-fold) and showed negligible activity on LAETG. We hypothesized that its specificity for LPESG was in part caused by the eSrtA(4S-9)(LPES) intermediate coupling more efficiently to GGG compared with the eSrtA(4S-9) (LPET) intermediate. To test this possibility, we measured K H of eSrtA(4S-9) for LPETG and LPESG, and observed that K H,LPETG (295 ± 18 μM) was nearly twice that of K H,LPESG (174 ± 32 μM). These results illustrate that eSrtA(4S-9) achieves its specificity via a combination of selectively binding LPESG over LPETG, as well as reduced stability of the mischarged SrtA(LPET) intermediate. Collectively, these features led to a ∼40-fold difference in transpeptidation of LPESG over LPETG by eSrtA(4S-9) (Fig. 3A) .
Similarly, eSrtA(2A-9) showed dramatically higher specificity than eSrtA for its target substrate, with a nearly 500-fold preference for LAETG over LPETG compared with eSrtA's 103-fold opposite starting specificity for LPETG over LAETG and negligible activity on LPESG. Measuring K H,LAETG (18.7 ± 3.3 μM) of eSrtA(2A-9) revealed that eSrtA(2A-9) has substantially improved hydrolytic stability compared with that of eSrtA (K H,LPETG = 32.8 ± 2.4 μM) and comparable to that of wild-type SrtA (K H,LPETG = 14.3 ± 0.8 μM) (SI Appendix, Table S3 ).
To test if eSrtA(2A-9) and eSrtA(4S-9) favor their respective targets over related peptides to a similar extent as that of wildtype SrtA (10) and eSrtA, we profiled the activity of eSrtA(2A-9), eSrtA(4S-9), and eSrtA on 20 variants of each of their respective peptide targets containing all possible amino acid substitutions at position 2 or position 4 (Fig. 3) . eSrtA(2A-9) exhibited strong specificity for the target LAETG peptide, with >20-fold reduced activity on the next most active substrates, LSETG and LRETG (Fig. 3E ) and no significant variation of K H across the tested substrates (Fig. 3F) . These results are consistent with a model in which position 2 does not significantly interact with the enzyme active site. In contrast, the specificity profile of eSrtA(4S-9) shows significant activity on the substrates LPEAG, LPECG, and LPESG ( Fig. 3 A and B) , comparable to that of eSrtA. However, measurement of K H of these enzyme-substrate pairs (Fig. 3C ) reveals that eSrtA(4S-9) has considerably improved thioester stability compared with eSrtA, with very little variation in K H among LPEAG, LPECG, LPESG, or LPETG and in sharp contrast to the significant K H variation observed in eSrtA. These data suggest that the observed specificity of eSrtA is a product of both substrate selectivity at the rate-determining thioester formation step, as well as the differential hydrolysis of mischarged acyl-enzyme complexes. Notably, both eSrtA and eSrtA(4S-9) exhibited a previously unreported activity for LPECG that exceeds that of LPETG in our assays.
Next, we dissected key structure-activity relationships among evolved sortases by reverting first-shell active site residues of both eSrtA(2A-9) and eSrtA(4S-9) back to that of eSrtA and assaying their respective activities (SI Appendix, Fig. S10 ). We selected residues 104, 118, and 182 for this study because of their close proximity to the positions 2 and 4 of the sorting motif. The eSrtA(2A-9) H104A reversion reverses the specificity change of eSrtA(2A-9), resulting in a 60-fold preference for LPETG over LAETG, compared with eSrtA(2A-9)'s 500-fold preference for LAETG over LPETG. In contrast, reversion of V182 in eSrtA (2A-9) lowers the activity level for LAETG, but maintains an 85-fold preference for LAETG over LPETG. These findings suggest that the identity of residue 104 strongly influences specificity at the second position of the sorting motif, whereas residue 182 is primarily involved in modulating overall protein activity.
Individually reverting the first-shell residues V104 and T118 in eSrtA(4S-9) resulted in promiscuous enzymes, lowering specificity for LPESG over LPETG by 14-fold for the V104A mutant and by 75-fold for the T118A mutant. Reversion of V182 in eSrtA(4S-9) preserved selectivity but decreased overall activity, consistent with the effect of this reversion in eSrtA(2A-9). Taken together, these results suggest that residues 104 and 118 both impact specificity at the fourth position of the sorting motif. In addition, thermal melt assays revealed that the eSrtA(2A-9) and eSrtA(4S-9) point mutants described above each possess modestly higher thermal stability than their respective eSrtA(2A-9) or eSrtA(4S-9) parental enzymes (SI Appendix, Fig. S9 B and C) , suggesting that the additional non-first-shell mutations in eSrtA (2A-9) and eSrtA(4S-9) increase protein stability to accommodate these critical specificity-and activity-enhancing mutations.
Collectively, these results establish that eSrtA(2A-9) and eSrtA(4S-9) evolved highly altered but quite stringent specificity, at least in part modulated through a novel process involving the differential hydrolytic stability of their acyl-enzyme intermediates. Both evolved round 9 clones strongly prefer their new LAXTG or LPXSG targets over the canonical LPXTG substrate, yet maintain comparable overall catalytic efficiency as that of eSrtA ( Fig. 3 and SI Appendix, Table S3 ). Importantly, both enzymes show nearcomplete orthogonality with respect to one another, with eSrtA(2A-9) showing >1,000:1 preference for LAETG over LPESG, and eSrtA(4S-9) showing similar preference for LPESG over LAETG.
eSrtA(4S-9) Modifies Endogenous Fetuin A in Human Plasma. In light of the known activity of eSrtA in human serum (18) and the highly altered specificity of the reprogrammed sortases, we hypothesized that eSrtA(4S-9) could catalyze the site-selective modification of endogenous LPXSG or LPXAG motifs in the human proteome. Based on an initial survey of the UniProt protein database (19), we identified 199 candidate proteins with LPXSG or LPXAG motifs known to exist in the human proteome. Cross-validation against the Plasma Proteome Database (20) identified 36 proteins known to be present at detectable concentrations in human plasma. Due to the frequent occlusion of such tags in their folded state, we speculated that only a small fraction of these 36 candidate proteins would be accessible by an enzyme.
We tested the ability of eSrtA(4S-9) to label proteins in human plasma by coincubating whole plasma with eSrtA(4S-9) in the presence of Gly-Gly-Gly-Lys(biotin) in the presence or absence of 10 mM CaCl 2 . Immunoblot and biotin capture each identified a single transpeptidation product (Fig. 4 C and D) , identified by mass spectrometry and confirmed by Western blot as fetuin A. As a systematic regulator of tissue mineralization (21), the selective in vivo and in vitro modification of endogenous fetuin A may be useful in the study of pathogenic biomineralization, as well as the diagnosis or potential treatment of fetuin-associated hemodialysis (22) and Plasmodium berghei pathogenesis (23) . Fetuin A contains an LPPAG sequence that our studies above suggest should be a substrate for eSrtA(4S-9), but should not be an effective substrate for eSrtA. Indeed, eSrtA showed no processing of fetuin A without supplemental calcium and only modest fetuin A conjugation efficiencies [90-fold lower than that of eSrtA(4S-9)] in the presence of 10 mM added CaCl 2 .
These findings demonstrate the ability of reprogrammed sortase enzymes to conjugate substrates to endogenous human proteins without chemical or genetic intervention. The high activity level of eSrtA(4S-9) in the absence of supplemental calcium demonstrates that evolved eSrtA variants can modify endogenous proteins with no additional cofactors.
Reprogrammed Sortases Enable the Facile Synthesis of Complex
Bioconjugates. The multiple modification of a protein's N and C termini using only a single SrtA enzyme is challenging due to competing reactions of protein oligomerization and circularization whenever a reactive C-terminal sorting peptide and N-terminal GGG are both present (SI Appendix, Fig. S3 ). Orthogonal SrtA variants have previously been used in the dual N-and C-terminal functionalization of target proteins (12, 24) . However, in these applications, the low activity and poor orthogonality of the enzymes greatly limited the scope of available reactions (24) . To test whether the combined use of reprogrammed sortases can overcome these limitations, we attempted to synthesize dual N-and C-terminally functionalized proteins of biomedical interest. Fibroblast growth factor 1 (FGF1) is currently being evaluated for the treatment of ischemic diseases but its efficacy is limited by low in vivo stability (25) and has recently been identified as a potential therapeutic agent for the treatment of type-2 diabetes (26). Fibroblast growth factor 2 (FGF2) is an angiogenic factor that has been investigated previously for use in wound healing (27) , but its translation into the clinic has also been limited by poor biostability (28) .
We expressed recombinant FGF1 and FGF2 as SUMO-TEV-GGG-FGF-LPESG-His 6 constructs [where SUMO indicates a small ubiquitin-like modifier tag (29) and TEV indicates a tobacco etch virus protease cleavage site]. Due to the close proximity of the FGF N and C termini, transpeptidation attempts using an unprotected N terminus, or using nonorthogonal enzymes, generated only circularized FGF (SI Appendix, Fig. S3 ). Instead, we used the evolved eSrtA(4S-9) to conjugate one of 10 kDa PEG-GGG, 10 kDa bis-PEG-GGG, 10 kDa 4-arm PEG-GGG, or 10 kDa biotin-PEG-GGG to the C terminus of FGF1 and FGF2. In situ cleavage of the linker by TEV protease exposed an N-terminal GGG, which was then conjugated to an Alexa Fluor 750-linked LAETG peptide using the evolved eSrtA(2A-9) to afford Alexa-LAETG-FGF-LPESG-PEG bioconjugates at moderate yield (15-30% at 8-mg scale, SI Appendix, Table S1 ) and in high purity (Fig. 4A) . Importantly, because the LPESGcontaining intermediates were not substrates for the orthogonal eSrtA(2A-9), no circularized byproducts were observed. These results establish that eSrtA(2A-9) and eSrtA(4S-9) form an orthogonal protein conjugation enzyme pair, enabling the direct synthesis of complex bioconjugates at substantially improved scale and yield relative to previous methods (12) . The facile and parallel synthesis of milligram quantities of dual PEG-and fluorophore-conjugated proteins of clinical interest may facilitate the high-throughput synthesis and screening of bioconjugates at scales relevant to preclinical studies.
eSrtA(2A-9) and eSrtA(4S-9) Modify Material Surfaces Orthogonally and with High Activity. Encouraged by the effectiveness of eSrtA (2A-9) and eSrtA(4S-9) for protein semisynthesis, we tested their potential utility for functionalizing surface materials. Although previous methods of biofunctionalization have been successful in generating materials with improved biocompatibility (30, 31) , these methods are only compatible with end-point immobilization of a single protein. Techniques for the orthogonal or multicomponent immobilization of several proteins to a single material target could enable the synthesis of more sophisticated proteinlinked materials.
To test the ability of our evolved eSrtA variants to selectively modify their cognate substrates in complex mixtures, we measured their ability to modify GGG-functionalized amphiphilic diblock polypeptide using fluorophore-conjugated LAETG or LPESG (SI Appendix, Fig. S2) , then further applied them to modify GGG-functionalized surfaces, rather than solution-phase materials. We generated GGG-PEG-functionalized 96-well plates, to which we added either Alexa Fluor 488-LAETGG or Alexa Fluor 647-LPESGG in the presence of eSrtA(2A-9), eSrtA (4S-9), or both. Each enzyme exhibited significant modification only on its cognate substrate, and each was capable of modifying surfaces to a high degree of functionalization when combined with its cognate substrate. The addition of both fluorescent peptide substrates and both orthogonal enzymes enabled simultaneous dual surface functionalization (Fig. 4B) . These results collectively demonstrate that eSrtA(2A-9) and eSrtA(4S-9) are capable of mediating the independent, simultaneous conjugation of multiple distinct compounds onto GGG-functionalized surfaces with very low cross-reactivity.
Discussion
We applied a modified yeast display selection strategy to evolve highly active eSrtA into reprogrammed, orthogonal variants eSrtA(2A-9) and eSrtA(4S-9) with a 51,000-or 120-fold change in substrate specificity, respectively. eSrtA(2A-9) and eSrtA(4S-9) both have catalytic activity comparable to that of eSrtA, but strongly prefer LAXTG and LPXSG substrates, respectively, over the wild-type LPXTG substrate. Substrate specificity profiling revealed that eSrtA(2A-9) strongly prefers the novel substrate LAXTG to the next most active peptide mutant at position 2, LSETG, whereas eSrtA(4S-9) showed pronounced acceptance of LPXCG and LPXAG substrates in addition to LPXSG. Mutational dissection of eSrtA(2A-9) and eSrtA(4S-9) revealed the importance of residue 104 on enzyme activity and specificity at sorting motif position 2. Likewise, we identified that the combination of residues 104, 118, and 182 strongly determined the activity and specificity at position 4 in the sorting motif.
We demonstrated the utility of SrtA reprogramming by showing that eSrtA(4S-9), unlike eSrtA or wild-type SrtA, is capable of modifying the human protein fetuin A in unmodified human plasma with high efficiency and specificity. In addition, we used these enzymes to synthesize the bioconjugates Alexa Fluor 750-LAETG-FGF1-PEG and Alexa Fluor 750-LAETG-FGF2-PEG, using a set of four different PEG building blocks, and to simultaneously and orthogonally functionalize GGG-linked surfaces with target peptides.
Consistent with the report of a promiscuous SrtA that processes XPETG peptides by Piotukh et al. (11) , we observed that eSrtA is capable of evolving significant changes in substrate specificity. Unlike this earlier report, however, here we demonstrate that SrtA may be further reprogrammed to possess fully altered, not merely broadened specificity. This capability is somewhat surprising given the mechanistic similarity between sortases and cysteine proteases (16) and the well-appreciated difficulty of the successful engineering of proteases with altered substrate specificities (32, 33) . We hypothesize a number of possible explanations for this success. The combination of positive and negative selection strategy may be more effective than previous evolution methods. The relatively large library sizes used in this work (up to 10 8 members), or our ability to precisely Table S1 ). The crude reactions were analyzed by SDS/PAGE and scanned for fluorescence at 700 nm. (B) Surface functionalization using eSrtA(2A-9) and eSrtA(4S-9). The 96-well plates coated with GGG-PEG (5 kDa) were incubated with enzyme and Alexa Fluor 488-LAETG (green) or Alexa Fluor 647-LPESG (red) for 2 h, then washed three times. The total fluorescence of the resulting surfaces was measured at 488 nm or 647 nm, then normalized to the fluorescence of samples containing eSrtA(2A-9) + 488-LAETG or eSrt(4S-9) + 647-LPESG. (C and D) Modification of endogenous fetuin A in human plasma treated with eSrtA(4S-9) for 2 h at room temperature in the presence of GGGK(biotin). (C) Western blot using Streptavidin-800 revealed a biotinylated protein conjugate of molecular weight ∼50 kDa, identified by mass spectrometry as fetuin A. (D) Conjugation efficiency in human plasma was 0.6% by eSrtA in the presence of supplemental calcium, and 1.8% or 57.6% by eSrtA(4S-9) in the absence or presence of supplemental calcium, respectively.
tune enzyme reaction conditions by adjusting the concentrations of exogenous substrates, also likely played a role in successful sortase evolution. We also speculate that sortase itself is a privileged scaffold for the evolution of altered substrate specificity. Given the low degree of sequence homology among strain-specific sortase enzymes, the high degree of sorting motif homology observed across Gram-positive bacteria, and the observed difficulty in previous sortase substrate engineering studies, the most likely contributor to our successful sortase evolution efforts is a combination of these potential explanations.
The high activity and specificity of eSrtA(4S-9) enabled the successful chemical modification in plasma of human fetuin A, the major carrier protein of calcium phosphate in vivo and a potent antiinflammatory protein and inhibitor of soft tissue calcification (21) . Although fetuin A is traditionally difficult to purify away from its natively interacting partners (34), our strategy of site-specific reaction and pull-down afforded pure preparations of truncated fetuin A without detectable contaminants. Additionally, the modification of fetuin A raises a number of new research and therapeutic opportunities, including the in situ stabilization of the protein to potentially effect mortality outcomes in hemodialysis (22) , the study of its proposed roles in hepatocyte invasion by P. berghei (23) , and its role in insulin sensitivity (35) .
The milligram-scale synthesis of protein-PEG conjugates demonstrates the effectiveness of orthogonal transpeptidases in the synthesis of complex biomolecules. The combination of two orthogonal, high-activity enzymes enabled the facile synthesis of 10 distinct fluorophore-FGF-PEG conjugates. Five of these were prepared at multimilligram scale. Given the growing use of bioconjugates as human therapeutics (36) and the recent therapeutic interest in FGF1 as a treatment for diabetes (26) , we anticipate that this technique may prove useful in the rapid generation and testing of a wide variety of protein-small molecule and protein-polymer constructs for use in research and therapeutic contexts.
Finally, our use of orthogonal eSrtA variants for the synthesis of peptide-conjugated surfaces illustrates the potential utility of our evolved SrtA variants for novel materials syntheses. By enabling the specific and orthogonal conjugation of proteins and material surfaces, we anticipate that orthogonal evolved sortases will enable the construction of previously inaccessible materials containing multiple, homogenously immobilized proteins.
The statistical rarity of a given peptide 5-mer within a typical proteome implies that a reasonably specific SrtA-derived transpeptidase is unlikely to react with more than a small number of targets. The applications achieved in this study, coupled with the generality of our eSrtA specificity changing strategy, suggest that it should be possible to reprogram sortases to selectively target other proteins of biological or therapeutic interest.
Methods
Methods for yeast library construction, gene isolation, 750-LAETG-FGF-LPESG-PEG production, plasma labeling of fetuin A, GGG-diblock functionalization, sortase and TEV protein expression and purification, and characterization of sortase variants are detailed in SI Appendix. The syntheses of GGGK-CoA, Abz-L(A/P)E(T/S)GK(Dnp) Alexa Fluor 750-LAETG, Alexa Fluor 488-LAETG, and Alexa Fluor 647-LPESG are described in the SI Appendix. Sortase and TEV protease expression and purification methods and protocols for in vitro characterization of described sortase variants are enclosed in SI Appendix.
